Catechol-containing compounds are a broad class of protein aggregation inhibitors: Redox state is a key determinant of the inhibitory activities

• Published in: Pharmacological research Vol. 184; p. 106409
• Main Authors: Velander, Paul, Wu, Ling, Hildreth, Sherry B., Vogelaar, Nancy J., Mukhopadhyay, Biswarup, Helm, Richard F., Zhang, Shijun, Xu, Bin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-10-2022
• Subjects: Aggregation modifying inhibitors; Alzheimer Disease - drug therapy; Amyloid beta-Peptides - metabolism; Amyloidogenic Proteins - metabolism; Animals; Anthraquinones; Catechol-containing compounds; Catechols - pharmacology; Catechols - therapeutic use; Diabetes Mellitus, Type 2; Drug library screening; HIP rats; Islet Amyloid Polypeptide - metabolism; Islet Amyloid Polypeptide - therapeutic use; Oxidation-Reduction; Protein Aggregates; Protein misfolding diseases; Quinones; Rats; Redox regulation; NIHCC; RFU; ThT; EGCG; Redox regulation; AFM; Catechol-containing compounds; HIP rats; PICUP; 7,8-DHF; RA; Nor; 3,4-DHBA; Aβ; Drug library screening; LC-MS; SAA; TCEP; TEM; Protein misfolding diseases; Aggregation modifying inhibitors; CA
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2022.106409

A range of neurodegenerative and related aging diseases, such as Alzheimer’s disease and type 2 diabetes, are linked to toxic protein aggregation. Yet the mechanisms of protein aggregation inhibition by small molecule inhibitors remain poorly understood, in part because most protein targets of aggregation assembly are partially unfolded or intrinsically disordered, which hinders detailed structural characterization of protein-inhibitor complexes and structural-based inhibitor design. Herein we employed a parallel small molecule library-screening approach to identify inhibitors against three prototype amyloidogenic proteins in neurodegeneration and related proteinopathies: amylin, Aβ and tau. One remarkable class of inhibitors identified from these screens against different amyloidogenic proteins was catechol-containing compounds and redox-related quinones/anthraquinones. Secondary assays validated most of the identified inhibitors. In vivo efficacy evaluation of a selected catechol-containing compound, rosmarinic acid, demonstrated its strong mitigating effects of amylin amyloid deposition and related diabetic pathology in transgenic HIP rats. Further systematic investigation of selected class of inhibitors under aerobic and anaerobic conditions revealed that the redox state of the broad class of catechol-containing compounds is a key determinant of the amyloid inhibitor activities. The molecular insights we gained not only explain why a large number of catechol-containing polyphenolic natural compounds, often enriched in healthy diet, have anti-neurodegeneration and anti-aging activities, but also could guide the rational design of therapeutic or nutraceutical strategies to target a broad range of neurodegenerative and related aging diseases.
[Display omitted]
•Parallel drug library screening identified catechol-containing compounds as a broad class of amyloid inhibitors.•Multiple secondary assays validated most of the identified inhibitors, including in vivo efficacy of rosmarinic acid.•Aerobic but not anaerobic conditions significantly enhanced anti-amyloid activities of the catechol-containing compounds.•Reducing biochemical agents blocked or diminished amyloid remodeling/inhibition activities of catechol-containing inhibitors.•Explain why catechol-containing compounds, enriched in healthy diet, have anti-neurodegeneration and anti-aging effects.